<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01260038</url>
  </required_header>
  <id_info>
    <org_study_id>TOGA 1001</org_study_id>
    <nct_id>NCT01260038</nct_id>
  </id_info>
  <brief_title>Study in NSCLC: is Timely Analysis of EGFR-mutation Status Feasible in Region Antwerp, Belgium.</brief_title>
  <acronym>HERMES</acronym>
  <official_title>Personalized 1st-line Treatment of Patients With NSCLC: is Timely Analysis of EGFR-mutation Status Feasible in a Routine Practice Setting in Antwerp.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Antwerp</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Universiteit Antwerpen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Antwerp</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an observational study to evaluate the feasibility of the implementation of a
      personalized treatment strategy based on specific tumor marker (f.i. EGFR-mutation) in the
      routine clinical care setting in the Antwerp region (Belgium).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The favourable results of a number of phase III-trials with gefitinib in NSCLC patients with
      activating EGFR-mutations, have resulted in the licensing of gefitinib in this indication.
      This offers the prospect of a true personalized treatment of patients with NSCLC.
      Implementation of such a personalized treatment strategy is dependent both on the
      availability of adequate tumor samples for the EGFR-mutation analysis and on the timely
      reporting of the mutation analysis results. Ideally the results should be available in all
      patients within 2 weeks of the analysis request.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>testing turn around time (in days)</measure>
    <time_frame>up to 1 month</time_frame>
    <description>how long does it take to get the mutation analysis result</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>demographics</measure>
    <time_frame>baseline</time_frame>
    <description>age, gender, tumor histology, smoking history</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>correlation between pulmonary function/pulmonary antecedents and EGFR-mutation status</measure>
    <time_frame>baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>correlation between family history with regards to cancer and EGFR-mutation status</measure>
    <time_frame>baseline</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">107</enrollment>
  <condition>Non Small Cell Lung Cancer</condition>
  <biospec_retention>None Retained</biospec_retention>
  <biospec_descr>
    <textblock>
      At diagnosis a tumor sample is collected for histological evaluation, this sample will be
      used for the biomarker analysis.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        newly diagnosed patients with Non Small Cell Lung Cancer
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age 18 years or above

          -  newly diagnosed NSCLC

          -  written informed consent

          -  tumor sample available

        Exclusion Criteria:

          -  mixed histology of small cell and NSCLC
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul R Germonpre, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UZA + Thoracale Oncologie Groep Antwerpen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Antwerpen</name>
      <address>
        <city>Edegem</city>
        <state>Antwerpen</state>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ Monica</name>
      <address>
        <city>Antwerpen</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GZA Sint Vincentius - Sint Augustinus</name>
      <address>
        <city>Antwerpen</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ZNA Middelheim - ZNA STER - ZNA Jan Palfijn</name>
      <address>
        <city>Antwerpen</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ St Jozef Bornem en Willebroek</name>
      <address>
        <city>Bornem</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ Klina</name>
      <address>
        <city>Brasschaat</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ St Dimpna</name>
      <address>
        <city>Geel</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ St Elisabeth</name>
      <address>
        <city>Herentals</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ Mol</name>
      <address>
        <city>Mol</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ Nikolaas</name>
      <address>
        <city>Sint-Niklaas</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ Turnhout</name>
      <address>
        <city>Turnhout</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>January 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 13, 2010</study_first_submitted>
  <study_first_submitted_qc>December 14, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 15, 2010</study_first_posted>
  <last_update_submitted>January 17, 2012</last_update_submitted>
  <last_update_submitted_qc>January 17, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 18, 2012</last_update_posted>
  <responsible_party>
    <name_title>Thoracale Oncologie Groep Antwerpen</name_title>
    <organization>Universiteit Antwerpen</organization>
  </responsible_party>
  <keyword>Non Small Cell Lung Cancer</keyword>
  <keyword>observational study</keyword>
  <keyword>EGFR mutation analysis</keyword>
  <keyword>EGFR mutation status</keyword>
  <keyword>testing turn around time</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

